Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRUM: Long-term Follow-up of OAV101 in SMA
NCT05335876Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2022
- Primary completion
- Apr 2031
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 19
01
Overview
A Phase 3 trial of onasemnogene abeparvovec in spinal muscular atrophy (SMA), sponsored by Novartis. Started Dec 2022; status: active, not recruiting.
02
Drugs
onasemnogene abeparvovec
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05335876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335876.